A Phase 1, Open-label, Single Dose Study to Evaluate the Concentration of RE104 and Its Major Metabolites in Breast Milk and Plasma of Healthy Lactating Women
Latest Information Update: 30 Oct 2024
At a glance
- Drugs RE-104 (Primary)
- Indications Postnatal depression
- Focus Pharmacokinetics
- Sponsors Reunion Neuroscience
- 30 Oct 2024 New trial record